Maria Caterina De Grandis

Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon

Andrea Pretta, Pina Ziranu, Eleonora Perissinotto et al. · British Journal of Cancer · 2024 · 22 citations · Full text

Medicine, Cancer Biology, Oncology +14

Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV

Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini et al. · European Journal of Cancer · 2023 · 18 citations · Full text

Medicine, Oncology, Pharmacology +17

FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · Journal of Clinical Oncology · 2023 · 17 citations

Medicine, Oncology, Pharmacotherapy +17

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO

P. Ciracì, M.M. Germani, F. Pietrantonio et al. · Annals of Oncology · 2025 · 11 citations · Full text

Medicine, Oncology, Pharmacology +13

Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable <i>RAS</i> and <i>BRAF</i> wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO.

Chiara Cremolini, Daniele Rossini, Sara Lonardi et al. · Journal of Clinical Oncology · 2022 · 10 citations

Medicine, Oncology, Pharmacotherapy +17